Fundraising Fox
Gilgamesh Pharmaceuticals
YC S20New York City, US · Founded 2019 · Delaware corporation · 15 employees · 33 known investors
Find your way into Gilgamesh Pharmaceuticals
Sign up to see every warm intro you have to Gilgamesh Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gilgamesh Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.
Also known as Gilgamesh Pharmaceuticals, Inc., Gilgamesh Pharma Inc.
Founders & leadership· Y Combinator alumni (S20)
Gilgamesh Pharmaceuticals was founded in 2019 by Jonathan Sporn, Andrew Kruegel, Dalibor Sames, and Andrew Kruegel, Ph.D..
Investors · 33
How we know: Aera VC's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us
How we know: press coverage · av.vc · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Frontier Path VC's portfolio page · Not right? Tell us
__Twitter.png)
How we know: Y Combinator's founder network · gaingels.com · Not right? Tell us
How we know: James Beshara Fund's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Noetic's portfolio page · Y Combinator's founder network · Not right? Tell us
How we know: Palo Santo VC's portfolio page · press coverage · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · pioneerfund.vc · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Prime Movers Lab's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · press coverage · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
How we know: PsyMed Ventures's portfolio page · Not right? Tell us
How we know: Strawberry Creek Ventures's portfolio page · Not right? Tell us
How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us
.jpeg){kind=logo}
How we know: a partner's Signal profile · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: press coverage · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: press coverage · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
Funding
SEC filings, press & company announcements$111.8M disclosed across 6 of 7 rounds · 2020–2026
- $60MSeries AMar 2026Source ↗
▶$13.8MraisedMay 2022 · 14 investors · PharmaceuticalsRule 506(c)
- Robert BermanDirector
- Gerard MarekExecutive Officer
- Phil SkolnickDirector
- Jonathan SpornExecutive Officer, Director
- Yoni FalksonExecutive Officer
- Thomas Kevin MurphyExecutive Officer
- Andrew KruegelExecutive Officer, Director
- Gaetano CrupiDirector
- Laszlo KissExecutive Officer
- Amy KruseDirector
- Offering amount
- $50M
- Amount sold
- $13.8M
- Minimum investment
- $50K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06c
▶$951offeredFeb 2022 · 1 investors · PharmaceuticalsRule 506(b)
- Robert BermanDirector
- Phil SkolnickDirector
- Amy KruseDirector
- Andrew KruegelExecutive Officer, Director
- Jonathan SpornExecutive Officer, Director
- Offering amount
- $951
- Minimum investment
- $951
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$34.7MraisedMay 2021 · 66 investors · PharmaceuticalsRule 506(b)
- Andrew KruegelExecutive Officer, Director
- Amy KruseDirector
- Robert BermanDirector
- Dalibor SamesDirector
- Jonathan SpornExecutive Officer, Director
- Offering amount
- $34.7M
- Amount sold
- $34.7M
- Minimum investment
- $10K
- Proceeds to insiders
- $630K
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$735KraisedSep 2020 · 10 investors · PharmaceuticalsRule 506(b)
- Dalibor SamesDirector
- Andrew KruegelDirector
- Jonathan SpornExecutive Officer, Director
- Amount sold
- $735K
- Minimum investment
- $10K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$150KraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
- Jonathan Sporn, M.D.Executive Officer, Director
- Andrew Kruegel, Ph.D.Executive Officer
- Thomas Kevin Murphy, Ph.D.Executive Officer
- Offering amount
- $150K
- Amount sold
- $150K
- Minimum investment
- $150K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$2.4MraisedJul 2020 · 25 investors · PharmaceuticalsRule 506(b)
- Thomas Kevin Murphy, Ph.D.Executive Officer
- Andrew Kruegel, Ph.D.Executive Officer
- Jonathan Sporn, M.D.Executive Officer, Director
- Amount sold
- $2.4M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Gilgamesh Pharmaceuticals went on to found or lead other companies.
Related companies · 6
Companies working in the same space as Gilgamesh Pharmaceuticals.
Legal entities · 1
corporate structureIn the news
Frequently asked questions
- What does Gilgamesh Pharmaceuticals do?
- Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.
- Who founded Gilgamesh Pharmaceuticals?
- Gilgamesh Pharmaceuticals was founded by Jonathan Sporn, Andrew Kruegel, Dalibor Sames, Andrew Kruegel, Ph.D. in 2019.
- Who are Gilgamesh Pharmaceuticals's investors?
- Gilgamesh Pharmaceuticals's investors include Aera VC, Alumni Ventures, Awareness Venture, Frontera Technology Ventures, Frontier Path VC, Gaingels, James Beshara Fund, JLS and 25 more.
- How much funding has Gilgamesh Pharmaceuticals raised?
- Gilgamesh Pharmaceuticals has disclosed $111.8M raised across 6 of its 7 known rounds.
- Where is Gilgamesh Pharmaceuticals headquartered?
- Gilgamesh Pharmaceuticals is headquartered in New York City, US.